About: HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 September 2002

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 2002 (uk) im September 2002 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en setiembre de 2002 (ast) scientific article published on 01 September 2002 (en)
publication date	wds:Q74605762-5DDE2E4D-ED37-48EF-B62B-151D402F3DF9
publication date	2002-09-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q74605762-02752739-94BE-4C9A-B3A7-2759390BBD2E wds:Q74605762-197E9D01-B826-4096-AA41-D84D384CD53D wds:Q74605762-26AC092A-C55A-4104-A4DA-A54B388702AA wds:Q74605762-5003595D-14A6-4F09-A363-46AD8B16464C wds:Q74605762-9E5197AD-C5D0-4B7E-98BE-82896BEFDF07 wds:Q74605762-A8B80196-487E-4019-92B8-D18A90FE75F2 wds:Q74605762-AB7FC519-D78F-4588-A573-19B52E4AB3F8 wds:Q74605762-CC299888-0223-4097-98EC-DD7ADCF02A41 wds:Q74605762-D3A5EB03-631C-4347-8531-F1D02B36A2C6 wds:Q74605762-F59B719D-4C29-4012-8D87-9B66212BF5A2
author name string	A John Barrett Neal S Young Jaroslaw P Maciejewski Yogen Saunthararajah Fausto Loberiza Ryotaro Nakamura Jeffrey Molldrem Jun-Mo Nam Jamie Robyn Toni Simonis
rdfs:label	HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome (en) HLA-DR15 (nl)
skos:prefLabel	HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome (en) HLA-DR15 (nl)
name	HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome (en) HLA-DR15 (nl)
title	wds:Q74605762-1A1D8440-32FE-455F-8D52-41AB66A6C938
title	HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome (en)
page(s)	wds:Q74605762-68C57F78-1106-4A14-B85E-594FB0543439
page(s)	1570-1574
instance of	wds:Q74605762-C6C01A64-5AAF-4D8A-BFD1-7AA9D3FC27DC
instance of	scholarly article
main subject	wds:Q74605762-6BFD9DD9-9AD3-4DA3-AFEE-DA3CE69F037C wds:Q74605762-71AB4451-2C98-47CE-B7CA-3C51F1B90B5B
main subject	aplastic anemia myelodysplastic syndrome
PubMed ID	wds:Q74605762-8CD08234-8BF0-40AC-B598-ABA9A77FA1C6
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12176872
PubMed ID	12176872
published in	wds:Q74605762-073A765B-7EF3-45CE-B035-EA19EAFE1A16
published in	Blood
issue	wds:Q74605762-B83CF775-0F4F-447A-BD1B-EEF0B7094697
volume	wds:Q74605762-2EF0B5ED-A8D4-4128-993A-409D50289B63
issue	5
volume	100
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q74605762
is cites work of	Immune Mechanisms in Myelodysplastic Syndrome Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy HLA-matched sibling transplantation for severe aplastic anemia: impact of HLA DR15 antigen status on engraftment, graft-versus-host disease, and overall survival. HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies Immune pathophysiology of aplastic anemia Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome Myelodysplastic syndromes: clinical practice guidelines in oncology Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome Current therapy of myelodysplastic syndromes Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome Managing myelodysplastic symptoms in elderly patients. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study Immunologic aspects of hypoplastic myelodysplastic syndrome. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia Immune pathophysiology of aplastic anemia A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response Current and future management options for myelodysplastic syndromes Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS). Immune dysregulation in myelodysplastic syndrome Clinical significance of a small population of paroxysmal nocturnal hemoglobinuria-type cells in the management of bone marrow failure Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes Myelodysplastic syndrome: An update on diagnosis and therapy Genetics of graft-versus-host disease: the major histocompatibility complex The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure Myelodysplasia: new approaches Myelodysplastic syndrome: an update on diagnosis and therapy Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15. Correlation analysis of severe aplastic anemia immunosuppressive therapy and human leukocyte antigen alleles in pediatric patients Immunosuppressive therapy for myelodysplastic syndromes: refining the indications Myelodysplastic syndrome. Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches Response to cyclosporine therapy in patients with myelodysplastic syndrome: a clinical study of 12 cases and literature review New agents in myelodysplastic syndromes Pediatric myelodysplastic syndromes. [Long- term outcome of thalidomide and cyclosporine in patients with IPSS low/intermediate- 1 myelodysplastic syndromes]. Placenta-Derived Adherent Stromal Cell Therapy for Hematopoietic Disorders: A Case Study of PLX-R18. Risk factors associated with poor response to immunosuppressive therapy in acquired aplastic anemia: A meta-analysis of retrospective studies The revolution of myelodysplastic syndromes
is cites work of	wds:Q26744500-6443FC35-E98D-48E4-B0DE-BED751EE7E3F

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software